Compare TPC & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPC | TLX |
|---|---|---|
| Founded | 1894 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | General Bldg Contractors - Nonresidential Bldgs | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.0B |
| IPO Year | N/A | N/A |
| Metric | TPC | TLX |
|---|---|---|
| Price | $68.30 | $9.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $82.00 | $21.00 |
| AVG Volume (30 Days) | ★ 540.3K | 81.9K |
| Earning Date | 11-05-2025 | 01-01-0001 |
| Dividend Yield | ★ 0.09% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $5,103,323,000.00 | $664,225,558.00 |
| Revenue This Year | $24.11 | N/A |
| Revenue Next Year | $11.90 | N/A |
| P/E Ratio | ★ N/A | $233.35 |
| Revenue Growth | 19.22 | ★ 55.35 |
| 52 Week Low | $18.34 | $8.76 |
| 52 Week High | $77.00 | $30.36 |
| Indicator | TPC | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 62.14 | 53.26 |
| Support Level | $58.11 | $8.76 |
| Resistance Level | $63.60 | $9.40 |
| Average True Range (ATR) | 2.62 | 0.24 |
| MACD | 0.70 | 0.06 |
| Stochastic Oscillator | 98.02 | 81.20 |
Tutor Perini Corp offers general contracting, construction management, and design-build services to private and public customers. The company constructs and repairs transportation infrastructure, water-treatment facilities, and a wide range of buildings. Tutor Perini has three operating segments: Civil, Building, and Specialty Contractors. A majority of its revenue is generated from the Civil segment, which specializes in public works construction and the replacement and reconstruction of infrastructure. Its civil contracting services include construction and rehabilitation of highways, bridges, tunnels, mass-transit systems, military and other government facilities, and water management and wastewater treatment facilities. Geographically, it derives key revenue from the United States.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.